|
|
|
|
|
|
|
Coherus BioSciences- Inc. (CHRS)
|
|
17.325 0.925 (5.64%)
|
06-20 11:07
|
|
Open:
|
16.55
|
Pre. Close:
|
16.4
|
|
High:
|
17.8
|
Low:
|
16.5
|
|
Volume:
|
418,865
|
Market Cap:
|
1145M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
16.979 - 17.06
|
17.06 - 17.134
|
|
Low:
|
14.946 - 15.033
|
15.033 - 15.112
|
|
Close:
|
16.247 - 16.4
|
16.4 - 16.538
|
|
|
|
Technical analysis (as of: 2018-06-20 10:57:22 AM)
|
|
Overall:
|
 
|
|
Stoxline posted a STRONG BUY today, upgraded from lower rating. This stock seems to be very strong for long buyers. If you bought, continue to hold stock until SELL signal. You are relatively safe as long as the SELL warning is not issued.
|
|
Target:
|
Six months: 20.79 One year: 24.28
|
|
Support:
|
Support1: 14.90 Support2: 13.10
|
|
Resistance:
|
Resistance1:
17.80 Resistance2: 20.79
|
|
Pivot:
|
15.82
|
|
Moving Averages:
|
MA(5): 15.78 MA(20): 15.71
MA(100): 12.61 MA(250): 12.30
|
|
MACD:
|
MACD(12,26):
0.40 Signal(12,26,9): 0.40
|
|
%K %D:
|
%K(14,3): 64.50 %D(3): 39.45
|
|
RSI:
|
RSI(14): 64.51
|
|
52-Week:
|
High: 17.8
Low: 8.05 Change(%): 9.8
|
|
Average Vol(K):
|
3-Month: 68135
10-Days 65717
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.CHRS has closed above the upper band by 11.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 19.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-06-13T17:32:45-04:00
With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
